Chopra K, Singh M, Gupta S, Ganguly N K
Department of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Methods Find Exp Clin Pharmacol. 1993 Sep;15(7):437-45.
The ability of a PAF antagonist, BN 52021, to limit myocardial infarct size in rat was assessed. Anesthetized rats were subjected to coronary artery ligation for 72 h and infarct size was measured macroscopically using TTC staining. Systolic blood pressure and ECG were monitored. BN 52021 (2.5 and 5 mg/kg i.v.) markedly reduced the infarct size, prevented the loss of R wave, an electrophysiological parameter of ischemic injury, reduced elevated serum MDA levels and demonstrated an inhibition of luminal-enhanced chemiluminescence. There was no marked change in glutathione peroxidase activity with BN 52021 treatment measured at various time intervals after coronary artery ligation. The beneficial effect of BN 52021 on ischemic injury may be due to specific inhibition of PAF-induced activation of neutrophils and consequent decreased amount of cytotoxic reactive oxygen species.
评估了PAF拮抗剂BN 52021限制大鼠心肌梗死面积的能力。将麻醉的大鼠进行冠状动脉结扎72小时，并用TTC染色宏观测量梗死面积。监测收缩压和心电图。静脉注射BN 52021（2.5和5mg/kg）可显著减小梗死面积，防止R波丢失（缺血损伤的电生理参数），降低升高的血清MDA水平，并显示出对管腔增强化学发光的抑制作用。冠状动脉结扎后不同时间间隔测量，BN 52021治疗组的谷胱甘肽过氧化物酶活性无明显变化。BN 52021对缺血性损伤的有益作用可能是由于特异性抑制PAF诱导的中性粒细胞活化以及随后细胞毒性活性氧物种数量的减少。
